Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes - Concepedia

Concepedia

Publication | Open Access

Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes

DOI Full Paper Access

1.1K

Citations

30

References

2005

Year

Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler, Chantal Mathieu, Leonard Kaufman, G Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,

New England Journal of Medicine

Abstract

Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes.

References

	Year	Citations
Glucose clamp technique: a method for quantifying insulin secretion and resistance. R. A. DeFronzo, J. D. Tobin, R Andres American Journal of Physiology-Endocrinology and Metabolism Priming InfusionArtificial PancreasNegative Feedback PrincipleMetabolic SyndromeInsulin Delivery	1979	7.4K
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus Kevan C. Herold, William Hagopian, Julie Auger, New England Journal of Medicine	2002	1.2K
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Lucienne Chatenoud, Éric Thervet, J Primo, Proceedings of the National Academy of Sciences ImmunologyPathologyImmunotherapyNonobese Diabetic MiceImmune Dysregulation	1994	646
TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes Mériam Belghith, Jeffrey A. Bluestone, Samia Barriot, Nature Medicine Overt Autoimmune DiabetesAutoimmune DiseaseAutoantibody ProductionDiabetesImmunology	2003	581
Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset C. R. Stiller, John Dupré, Michael Gent, Science	1984	557
CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET G Feutren, R Assan, Gérard Karsenty, The Lancet Metabolic SyndromeDiabetes ManagementInsulin ManagementDiabetesPharmacology	1986	448
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice Lucienne Chatenoud, J Primo, J F Bach The Journal of Immunology	1997	414
C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus O. K. Faber, C Binder Diabetes	1977	386
RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN-2, AND GAMMA-INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS Daniel Abramowicz, Liliane Schandené, Michel Goldman, Transplantation	1989	361
IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION Lucienne Chatenoud, Christiane Ferran, Christophe Legendre, Transplantation ImmunologyImmune RegulationCell DeathPathologyRenal Inflammation	1990	319

Page 1